Health iQ Limited, Office 213, 23 Austin Friars, London, EC2N 2QP
Mon - Fri: 9:00AM - 17:00PM Sat - Sun: Closed
+ 44 (0)20 3542 5338
Welcome to MedicalPress a Premium Medical Theme
+44 (0) 20 3542 5338

Free resources

  • Doctors have postponed more than 2m operations after non-emergency surgery was cancelled for at least three months to free up beds for coronavirus patients. The mounting backlog of procedures could cost the NHS £3bn to work through and may require many of the 20,000 doctors and nurses who have returned to the health service to stay on once the Covid-19 crisis has been brought under control.

  • A quantitative survey of more than 5,700 patients with chronic conditions, conducted by Arlington, Virginia-based HealthiVibe, shows that 50% of those already in poor health believe the quality of their medical care is worse or much worse now, only a short time after the adoption of strict social distancing and self-isolation measures in the United States in the advent of the COVID-19 pandemic.  The results of the survey highlight the unique challenges faced by those with chronic conditions in the current environment, and suggest a possible long-term impact on an

  • Almost 18,000 more people with cancer in England could die after the coronavirus pandemic led hospitals to suspend treatment and deterred patients from seeking NHS care, research has found. Cancer experts claim that an extra 6,270 people in England who have been newly diagnosed with the disease could die from it over the next 12 months as a direct result of the disruption caused by coronavirus, and the additional toll taking into account all those living with cancer could be 17,915.

  • The health service’s response to COVID-19 has far-reaching consequences that are being felt across specialties and therapy areas. In a bid to free-up critical care capacity, NHS England has recently published a set of guidelines that transform patient pathways and impact demand. They change how and where care is provided, reduce elective appointments and, in some cases, restrict the number of new patients able to access services.

  • To respond best to the changes driven by the COVID-19 pandemic, pharma companies should consider reorienting their commercial models to fit the needs of healthcare providers and patients better.